Close contact interferon-gamma response to the new PstS1<sub>(285–374)</sub>:CPF10: a preliminary 1-year follow-up study

Leonardo Silva de Araujo¹, Nidai de Bárbara Moreira da Silva Lins¹, Janaina Aparecida Medeiros Leung², Fernanda Carvalho Queiroz Mello² and Maria Helena Féres Saad¹*

Abstract

Background: The available diagnostic tools for latent tuberculosis (TB) infection (LTBI) via interferon-gamma (IFN-g) release assays (IGRA) are based on ESAT6:CFP10 stimulation. However, the mycobacterial antigen PstS1 is also highly immunogenic and some of its fragments, such as PstS1<sub>(285–374)</sub>, have shown higher immunoreactivity in LTBI than in active TB. PstS1<sub>(285–374)</sub>, therefore, could increase the accuracy of the existing IGRA to detect LTBI. Thus, a new chimeric protein has recently been developed (PstS1<sub>(285–374)</sub>:CFP10) showing potential for LTBI screening of recent close contacts (rCt) exposed to Mycobacterium tuberculosis. The aim of this study was to analyze the PstS1<sub>(285–374)</sub>:CFP10 longitudinal IFN-g profile in comparison to ESAT6:CFP10 and full PstS1/CFP10 stimulation in a rCt cohort and correlate the responses to these in-house IGRA with any clinical changes/interventions that might occur.

Methods: A free-of-cost, one-year follow up was offered to 120 rCt recruited in Rio de Janeiro, RJ, Brazil. Whole blood short-term (WBA), long-term stimulation (LSA) assays, and the tuberculin skin test (TST) were performed during follow up.

Results: Among the enrolled rCt, 44.2% (53/120) returned for re-evaluation and the control group (TST negative, n = 17) showed low IFN-g reactivity to all antigen stimulations during the entire follow up, except for one participant who had shown radiological evidence of past TB/LTBI. Both incident cases were detected by IGRA-PstS1<sub>(285–374)</sub>:CFP10 during LTBI and after disease progression. Moreover, subsequent to the prophylactic treatment for LTBI (tLTBI), a significant regression in the LSA response was predominantly observed through stimulation of the new chimeric protein (8/10, 80%) followed by ESAT6:CFP10 (5/10, 50%) and PstS1/CFP10 (4/10, 40%). No clinical or epidemiological characteristics were exclusively shared among IGRA convertors.

Conclusion: It was demonstrated that the TST negative rCt without radiological evidence of LTBI/TB did not develop an IGRA-PstS1<sub>(285–374)</sub>:CFP10 response during the one-year follow up. Moreover, all incident cases were detected by our new IGRA; and a significant decrement of LSA-PstS1<sub>(285–374)</sub>:CFP10 reactivity post-prophylactic tLTBI was found. To our knowledge, this is the first study to monitor changes in the immune response profile of IGRA-PstS1<sub>(285–374)</sub>:CFP10 among rCt during a consecutive one-year period, thus providing additional evidence of its potential in the detection of LTBI.

Keywords: M. tuberculosis, Tuberculosis, LTBI, Interferon-gamma, Follow up

*Correspondence: saad@ioc.fiocruz.br

1 Laboratory of Cellular Microbiology, Oswaldo Cruz Institute, Fiocruz, Avenida Brasil, 4365, Rio de Janeiro, RJ 20045-360, Brazil

© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
**Background**

Despite the availability of efficient antibiotic treatments, the control of tuberculosis (TB) remains a challenge worldwide [1–3]. After an initial *Mycobacterium tuberculosis* (*Mtbc*) infection, approximately 10% will develop TB. The great majority (roughly 90%), however, is expected to control the bacterial replication and present latent infection (LTBI) while under the constant risk of developing the active form [4].

In active disease, clinical manifestations may help diagnose pulmonary TB [5]. In contrast, LTBI is asymptomatic and the lack of adequate diagnostic methods to detect latent infection tend to hamper attempts at preventing new incident cases even though the isoniazid preventive treatment for LTBI (tLTBI) has been found to reduce the risk of developing TB by as much as 90% [2, 6].

For over a century, LTBI diagnoses have relied on the relatively simple, low-cost, tuberculin skin test (TST) [7]. However, false-positive results may occur in the TST due, in large part, to a previous exposure to environmental non-tuberculous mycobacteria [8]. TST also includes the boosting phenomenon and the need for a reading visit [9]. After development of the commercial interferon-gamma (IFN-γ) release assay (IGRA), a new tool emerged [9]. After development of the commercial interferon-gamma (IFN-γ) release assay (IGRA), a new tool emerged [9].

The TB Control Program offered clinical follow up to all contacts (rCt) exposed to a pulmonary TB index case (IC). All participants were recruited from the general patient population seeking treatment at the public health care facilities located in the City of Rio de Janeiro. The present study correlated the modulations detected in WBA and LSA responses under PstS1(285–374):CFP10, PstS1/CFP10, and ESAT6:CFP10 stimuli resulting from clinical changes and antibiotic interventions.

**Methods**

**Study samples**

The present investigation was carried out on samples previously collected by the TB Control Program at the Clementino Fraga Filho University Hospital in Rio de Janeiro, RJ, Brazil [13]. All rCt recruited between March 2010 and August 2012 were >17 years of age and tested negatively for the human immunodeficiency virus (HIV). Upon obtaining informed oral and written consent, blood samples were collected prior to administering the Mantoux TST [13].

According to Brazilian Ministry of Health recommendations [14], all close contacts showing a TSTpos (cut-off ≥5 mm) with no indication of disease were considered LTBI or as having pulmonary TB in light of their respective microbiological, radiological, and clinical findings and were subsequently offered specific free-of-cost treatment.

**Prospective analysis**

The TB Control Program offered clinical follow up to all rCt and the TST negative cases were restested at four-month intervals and after the twelfth month, while TST positive subjects were just treated and clinically followed. In a previous study [13] by our group analyzing the potential use of PstS1(285–374):CFP10 as a new LTBI biomarker, blood samples were taken upon enrollment (T₀). In the present study, the rCt were followed up longitudinally for a year (T₁), except for the TST converters and incident cases, from whom blood was collected upon a skin test conversion or TB diagnosis. For the in vivo TST, a conversion was classified as an augmentation of ≥10 mm in comparison to a previously reported test. Conversely, for the in vitro WBA and LSA, a conversion/regression response was defined as a respective augmentation or decrement that crosses the cut-off points in the follow-up tests in comparison to baseline reactivity.
**Mycobacterium tuberculosis antigens**

The *Mtbg* recombinant antigens ESAT6:CFP10 and PstS1/CFP10 were kindly provided by Dr. Tom Ottenhoff (Leiden University Medical Centre, The Netherlands) and Dr. Mahavir Sigh (Helmholtz Centre for Infection Research, Germany), respectively. The chimeric protein PstS1(285–374):CFP10 was produced in our laboratory, as previously described [13]. In brief, sequences of the selected genes were amplified from *M. tuberculosis* H37Rv genomic DNA using gene-specific primers. Each fragment was then cloned, fused, and transformed for recombinant expression in *Escherichia coli*.

**Whole blood (WBA) and peripheral blood mononuclear cell (PBMC) long-term stimulation assays (LSA)**

As previously described [13], heparinized venous blood was collected and separated for WBA (1 mL per well for 22 h) or for PBMC isolation followed by LSA (1 mL per well, 5 days) in the presence or absence of Concanavalin-A/antigens. The culture supernatants were collected and stored at −20 °C until tested.

The commercial ELISA Duo-Set-IFN-γ kit (R&D, USA) was used to evaluate IFN-γ secretion following the manufacturer's recommendations. After subtraction of the appropriate unstimulated control, the results were expressed in picograms/milliliters (pg/mL). All cut-off points were previously standardized (WBA: ESAT6:CFP10 = 10 pg/mL; PstS1/CFP10 = 10.5 pg/mL; PstS1(285–374):CFP10 = 29.5 pg/mL; LSA: 100 pg/mL each) [13].

**Data analysis**

Prism5 (GraphPad Software, USA) and SPSS 17.0 (IBM, USA) were used to generate plots and for statistical analyses. The Mann–Whitney and Kruskal–Wallis non-parametric tests were utilized to analyze significant differences between 2 or >2 groups, respectively. The Wilcoxon Signed Rank Test was adopted for longitudinal analyses. *P* values of <0.05 were considered significant.

**Results**

**Study participants**

According to Brazilian Ministry of Health guidelines, a clinical evaluation/follow up and TB prophylaxis are not mandatory after reported exposure to *Mtbg*. Of all enrolled rCt, 44.2% (53/120) returned for the 1-year re-evaluation. They were then organized into study groups according to their baseline TST and clinical outcomes, as follows: Group I, TST negative (TSTneg; WBA, n = 10; LSA, n = 17); Group II, TST conversion (WBA, n = 2; LSA, n = 4); Group III, TSTpos submitted to tLTBI (WBA, n = 17; LSA, n = 25); Group IV, TSTpos untreated (WBA, n = 4; LSA, n = 5); and Group V: TB incident cases (WBA, n = 2; LSA, n = 2) (Fig. 1).

As shown in Table 1, while nearly half (49.1%) of the enrolled rCt inhabited the same dwelling as their IC, the proportions of gender and BCG vaccination status were slightly asymmetrical (58.5% was female and 62.3% had a BCG vaccination scar). The mean ages were similar among all groups, varying between 43.5 (±14.4) and 46.4 (±18.5) years of age (p ≥ 0.051), except for Group V (61.5 ± 3.5 years, p = 0.023). As expected, there was a statistical difference (p ≤ 0.016) when comparing mean skin test induration between TSTpos (Group III or IV) and TSTneg (Group I or II) rCt.

**IGRA reactivity**

Due to ethical limitations, the adequate amount of blood for both assays was unavailable for some rCt, thus justifying the discrepancies between the sample sizes of WBA and LSA.

With the exception of one outlier at T1 (Black circle, Fig. 2a) who had a TB compatible chest x-ray since 1978 with no other clinical manifestations, the mean amount of IFN-γ detected in Group I was similarly low at the two time-points for both IGRA (p ≥ 0.109). In contrast, the PBMCs of participants with a TST conversion (Group II, Fig. 2b) or untreated TSTpos (Group IV, Fig. 2d) demonstrated a slight-to-moderate increase in their mean IGRA responses (p ≥ 0.109).

An exclusive, antagonistic IFN-γ modulation during short-and long-term incubation periods was noticed in Groups III (tLTBI) and V (TB). While the mean LSA response dropped post-tLTBI (Fig. 2c, p ≥ 0.071), the WBA response increased (p ≥ 0.084). Interestingly, the Group V response was the opposite: the mean WBA response dropped and LSA increased along the follow-up period, principally in relation to ESAT6:CFP10 and PstS1(285–374):CFP10 (Fig. 2e, p ≥ 0.18).

Despite the tendencies regarding IFN-γ modulation, no statistically significant changes were identified when comparing paired IFN-γ mean ± standard deviation (SD) reactivity to any antigenic stimulation (Fig. 2, p ≥ 0.071). The same was observed for concanavalin A (p ≥ 0.087) in both the WBA (mean ± SD, pg/mL: T0 = 74.1 ± 99.0 and T1 = 84.2 ± 97.6; n = 35) and LSA (mean ± SD, pg/mL: T0 = 2268.9 ± 1831.1 and T1 = 1704.9 ± 874.8; n = 55). All the mean IFN-γ responses are shown in Additional file 1: Table S1.

Interferon-gamma response regressions or conversions were observed in some rCt. Either WBA or LSA conversions occurred in all individuals regardless of group (WBA-convertors: Group I: 5/14 [35.7%]; Group II: 1/14 [7.1%]; Group III: 7/14 [50%]; Group IV: 1/14 [7.1%]. LSA-convertors: Group I: 3/13 [23.1%]; Group II: 2/13 [15.4%]; Group III: 5/13 [38.5%]; Group IV: 2/13 [15.4%]; and Group V: 1/13 [7.6%]) as well as to all antigens (Fig. 3
However, no clinical or epidemiological characteristics were exclusively shared among the IGRA converters. Conversely, regression from a previously positive IFN-γ response was mostly seen in Group III whatever the stimulus (Group III regressors/Total regressors: WBA: 6/9, 66.7%; LSA: 10/12, 83.3%), but principally to the new PstS1(285–374):CFP10 antigen (WBA: ESAT6:CFP10: 2/9, 22.2%; PstS1:CFP10: 7/9, 77.8%; PstS1(285–374):CFP10: 8/9, 88.9%. LSA: PstS1:CFP10: 4/12, 33.3%; ESAT6:CFP10: 7/12, 58.3%; PstS1(285–374):CFP10: 8/12, 66.6%) (Fig. 3 c, d).

Effects of tLTBI on in-house IGRA responses

Despite the presence of a TST positive reaction, some of the rCt submitted to tLTBI lacked baseline IGRA reactivity. We, thus, opted for the stratification of Group III individuals according to their baseline IFN-γ response (responders/non-responders) to each stimulus (Fig. 4). No statistical significant changes were observed in the sub-cohort of non-responder rCt. On the other hand, there was a statistically significant decrease among the LSA-responders to ESAT6:CFP10 (from 758.5 ± 731 to 231.2 ± 240.1 pg/mL, p = 0.027) as well as to PstS1(285–374):CFP10 (from 588.6 ± 650.0 to 106.7 ± 288.4 pg/mL, p = 0.004), albeit with a borderline significance relative to the full PstS1/CFP10 combination (from 469.2 ± 306.8 and 28.0 ± 45.7 pg/mL, p = 0.06). One rCt preventively treated with isoniazid did not show any significant changes in IGRA response modulation over time (Fig. 4).

Table 1 Baseline demographic characteristics of the study population

| Baseline characteristics | All (100) | Group I (7,5) | Group II (47,2) | Group III (9,4) | Group IV (3,8) | Group V (3,8) |
|--------------------------|-----------|--------------|----------------|----------------|----------------|--------------|
| BCG scar                 | 33 (62.3) | 9 (52.9)     | 4 (100)        | 18 (72)        | 2 (40)         | 0 (0)        |
| Females                  | 31 (58.5) | 8 (47.1)     | 3 (75)         | 16 (64)        | 3 (60)         | 1 (50)       |
| Household contact         | 26 (49.1) | 5 (29)       | 2 (50)         | 10 (40)        | 2 (40)         | 2 (100)      |
| Mean (±SD) age, years     | 45.1 (±13.2) | 43.9 (±13.0) | 43.5 (±14.4)   | 44.5 (±12.6)   | 46.4 (±18.5)   | 61.5 (±3.5)* |
| Mean (±SD) TST induration, mm | 7.2 (±4.1) | 0.4 (±1.2)   | 1.8 (±2.1)     | 11.8 (±3.7)**  | 9.8 (±3.6)**   | 12.5 (±3.5)* |

Group I TSTpos, Group II TST converters, Group III TSTpos submitted to treatment for latent tuberculosis infection (tLTBI), Group IV TSTpos not submitted to the tLTBI, and Group V developed active pulmonary TB. Mann–Whitney test was used to generate p values

* BCG Bacille Calmette Guérin, mm millimeters, TST tuberculin skin test, SD standard deviation

The symbols * and ** were used to identify p values <0.05 comparing to Group I or II, respectively
White square). Of note, his/her respective IC was later diagnosed with MDR-Mycobacterium tuberculosis (multidrug resistant to isoniazid and rifampicin) infection.

**Discussion**

Diagnostic tests to accurately detect an invasive microbe play key roles in patient management and the control of infectious diseases [15]. A previous exploratory investigation conducted by our group showed that, among TB cases, the combination of full PstS1 with CFP10 induced IFN-γ response levels similarly to what occurred following ESAT6:CFP10 stimulation [16]. In another study, differential immune responses to PstS1 peptides were observed [17]. It was also found that the peptide included in our PstS1(285–374):CFP10 fusion protein induced higher T cell proliferative responses in LTBI compared to pulmonary TB donors [17]. Additionally, despite the very low-level expression of the PstS1 protein by M. bovis BCG [18], the high immunogenicity of this protein during TB has been proven in a variety of studies [16, 17, 19–22]. In fact, we have likewise reported [13] a similarly high specificity, for LTBI detection, in PstS1 (285–374):CFP10 and ESAT6:CFP10 IFN-γ responses (~90% specificity) [13], including those to the full PstS1/CFP10 (personal communication). Nevertheless, among TSTposer contacts, the chimeric protein had the highest detection rate (WBA: 23/54, 42.6%; LSA: 26/54, 48.2%), followed by ESAT6:CFP10 (WBA: 18/54, 33.3%; LSA: 24/54, 44.4%) [13], and PstS1/CFP10 (WBA: 20/54, 33.3%; LSA: 22/54, 40.7%, personal communication). Since the new immunogenic fusion protein PstS1(285–374):CFP10 seems to be more suitable for adding sensitivity to ESAT6:CFP10 than the full PstS1/CFP10 combination, it was decided to investigate further. Indeed, there is much evidence suggesting that IGRA-ESAT6:CFP10 will be false-negative in a significant proportion of both latent and actively-infected Mtb individuals [23]. However, in the absence of a gold-standard test for LTBI, questions arose concerning the practical significance of detecting TSTposer/ESAT6:CFP0poser/PstS1(285–374):CFP10poser individuals. Thus, longitudinal studies with individuals recently exposed to Mtb should help to clarify any remaining doubts concerning the absolute reliability of the newly-proposed LTBI diagnostic method.

The mechanisms involved in the progression from LTBI to TB are not yet fully understood. The development of TB is associated with a failure in the immune surveillance system of the host with a Th2 polarization that inhibits the host protective Th1 response (IFN-γ, interleukin-12, and tumor necrosis factor [24–27]. The incident cases presented a coincident decrement of WBAs, probably due to an inefficient activation of effector Th1 cell repertoires [26]. As seen in Fig. 2e, however, by LSA, memory and resting T cells with a longer incubation period were able to differentiate and initiate IFN-γ production [28–30]. Other studies have shown similar IFN-γ responses in such assays [30–33]. In the end, these occurrences might reveal that some of the host cell populations would still be able to mount a Th1-IFN-γ response to Mtb antigens even after the development of TB. It is
noteworthy that the small sample size may have limited our ability to detect a significant modulation. As such, it is clear that additional studies are required to validate or not the reported dichotomic IGRA modulation during TB progression.

Individuals from different groups not sharing any independent, mutually exclusive clinical or epidemiological risk factors demonstrated an IGRA conversion. To elucidate these cases, it must be taken into account that: (1) An IGRA response may be affected by a prior TST since the test consists of the intradermal inoculation of a *Mtb* crude antigenic pool [34]; (2) in a high-transmission setting such as Rio de Janeiro, re-exposure to *Mtb* often leads to the maintenance or incensement of the IFN-γ responses [35, 36]; and (3) the lack of a baseline (T₀) response may be due to the “window period” between exposure to a pathogen and development of an adaptive response. A dynamic characteristic of the IGRA response over time has been previously described [37], Thus, the idea that minor non-specific differences in the IFN-γ response should also be expected. Nonetheless, the reversion to negativity predominantly seen in Group
III (Fig. 3) corroborates previous findings regarding LTBI [34, 35, 38–40] and TB [41, 42] individuals receiving anti-biotic therapy. Of note is the recent contact of a MDR-TB index case who did not demonstrate a LSA regression post-tLTBI with isoniazid, suggesting that antibiotics were ineffective in this case (Fig. 4, White square). It, therefore, could be surmised that the new LSA PstS1(285–374):CFP10-based might prove useful in monitoring changes in the immune response after completion of preventive therapy.

In the present study, both WBA and LSA displayed a few discordant results. Similar data have been gathered via commercial kits [13, 43]. This result was not surprising since the responses of different immune cell subsets are elicited in short- and long-term cultures [28, 29]. From an operational standpoint, WBA is faster, more cost-effective, and easier. Contrariwise, a significant post-tLTBI regression response during the follow-up period only occurred in LSA (Fig. 3). Therefore, in settings in which higher sensitivity is required, an approach that could be considered would be combining both test results to characterize LTBI [28] since WBA and LSA have particularities that must be reckoned with before application. It should be emphasized that all TB incident cases were detected by WBA-PstS1(285–374):CFP10, LSA-PstS1(285–374):CFP10, and TST, but that the IGRA tests showed better selectivity among the 108 rCt (WBA-PstS1(285–374):CFP10: 28/108, 25.9%; LSA-PstS1(285–374):CFP10: 31/108, 28.7%; TST: 54/108, 50%) [13]. Moreover, the IGRA PstS1(285-374):CFP10-based showed moderate-to-substantial kappa (κ) agreement under ESAT6:CFP10 stimulation in WBA and LSA (κ = 0.50–0.71), respectively [13]. If these findings are corroborated in further investigations, the use of any of the newly-proposed IGRAs instead of TST may be able to reduce the number of unnecessary tLTBI prescriptions.

**Conclusion**

This is the first study to monitor changes in the immune response profile of the IGRA PstS1(285–374):CFP10-based among rCt during a 12-month period. As a result, additional information has been acquired about this new LTBI biomarker in an effort to highlight its potential. Without a doubt, the sample size and prophylactic tLTBI are limitations, which may contribute to an underestimation of the negative/positive predictive values of the test to detect TB progression. However, it is our belief that the participants in our study groups accurately reflect the public at large in routine clinical practice in a scenario with a high TB-burden and BCG vaccination coverage, in which prior *Mtb* exposure or re-exposure after initiating tLTBI cannot be ruled out even with respect to TST\textsuperscript{Tes}/ESAT6:CFP10\textsuperscript{Tes}.

**Fig. 4** Longitudinal interferon-gamma responses post-prophylactic treatment for latent tuberculosis infection. Longitudinal analysis upon enrollment (T\textsubscript{0}) and after 1-year follow up (T\textsubscript{1}) of mean interferon-gamma levels via short- (WBA) and long-term (LSA) stimulation assays with blood specimens from recent close contacts of TST\textsuperscript{Pos} treated for latent tuberculosis infection (Black circle) and stratified according to their baseline interferon-gamma response (non-responders and responders) to each *Mycobacterium tuberculosis* antigen: **a** ESAT6:CFP10, **b** PstS1/CFP10, and **c** PstS1(285–374):CFP10. \*p < 0.05 via Wilcoxon signed rank test. White square recent close contact exposed to a multidrug-resistant *Mycobacterium tuberculosis* strain.
individuals [2]. Interestingly, except for one outlier with radiological evidence of long-term LTBI, Group 1 participants (TST	extsuperscript{neg}, n = 17) continued having a very low IFN-γ response to PstS1	extsuperscript{285–374}:CFP10-based WBA and LSA during the entire follow up (Additional file 1: Table S1). LSA regression was predominantly observed among rCt submitted to tLTBI (Group III, PstS1	extsuperscript{285–374}:CFP10 [n = 09], p < 0.05, Figs. 3 and 4). In addition, both incident cases were detected early by IGRA-PstS1	extsuperscript{285–374}:CFP10 before showing microbiological evidence of active pulmonary TB. Together, these data provide more positive evidence about the potential of IGRA-PstS1	extsuperscript{285–374}:CFP10-based for LTBI diagnoses. It is of utmost importance that low- and middle-income countries invest in the development of accurate, reliable, and cost-effective LTBI diagnostic tools to ensure the proper maintenance of their TB control programs. In light of the previous [13] and present evidence, we are encouraged to proceed to a next-step: validation of the use of IGRA-PstS1	extsuperscript{285–374}:CFP10 in cohorts from different geographical areas worldwide.

Additional file

Additional file 1: Table S1. Mean, standard deviation (SD), IFN-γ reactivity of whole-blood stimulation.

Abbreviations

TB: tuberculosis; LTBI: latent tuberculosis infection; tLTBI: treatment for latent tuberculosis infection; rCt: recent close contacts; IFN-γ: interferon-gamma; IGRA: interferon-gamma release assay; WBA: Whole blood short-term assay; LSA: long-term stimulation assay; Mtbc: Mycobacterium tuberculosis; TST: tuberculin skin test; pos: positive; neg: negative; RD1: region of difference 1; Th: T helper; BCG: Bacillus Calmette-Guérin; pg/mL: picograms/milliliter.

Authors’ contributions

Study concept and design: MHFS, FQM; data acquisition: LSA, NBMS, JAML; sample collection: LSA, NBMS, and JAML; data analysis and interpretation: MHFS, LSA; drafting of the article and critical review of important intellectual content: MHFS, LSA; approval of the final version: LSA, NBMS, JAML, FQM, and MHFS. All authors read and approved the final manuscript.

Author details

1 Laboratory of Cellular Microbiology, Oswaldo Cruz Institute, Fiocruz, Avenida Brasil, 4365, Rio de Janeiro, RJ 20045-360, Brazil. 2 Federal University of Rio de Janeiro, Hélio Fraga Filho Hospital, Professor Rodolpho Paulo Rocco Street, 255, 1st Floor, Ilha do Fundão, Rio de Janeiro, RJ 21941-913, Brazil.

Acknowledgements

We are most grateful to Drs. Tom Ottenhoff and Mahavir Singh for kindly providing the antigens and Judy Greven for editing the text.

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

A hard copy of all raw data obtained is available at the registries of the laboratory upon request. However, the raw data will not be shared in the present report since they include additional information that could be used for further analysis at a later date.

Ethical consent

The present study was approved by the National Ethics Committee in Human Research (#560-10).

Upon informed oral and written consent, blood was collected from all the participants.

Funding

This work was supported by grants from the Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro, the Conselho Nacional de Desenvolvimento Científico e Tecnológico, and the Programa de Excelência em Pesquisa/FOCRUZ/Oswaldo Cruz Foundation, Brazil.

Received: 4 April 2016 Accepted: 21 December 2016

Published online: 23 January 2017

References

1. Implementing the WHO Stop TB Strategy: a handbook for national tuberculosis control programmes. Geneva: World Health Organization; 2008.
2. Steffen RE, Caetano R, Pinto M, Chaves D, Ferrari R, Bastos M, de Abreu ST, Menzies D, Trajman A. Cost-effectiveness of quantiferon®-TB gold-in-tube versus tuberculin skin testing for contact screening and treatment of latent tuberculosis infection in Brazil. PloS ONE. 2013;8(4):e59546.
3. El-Sadi WM, Porfman D, Denning E, Matts JP, Cohn DL. A review of efficacy studies of 6-month short-course therapy for tuberculosis among patients infected with human immunodeficiency virus: differences in study outcomes. Clin Infect Dis. 2001;32(4):623–32.
4. Ahmad S. Pathogenesis, immunology, and diagnosis of latent Mycobacte-rium tuberculosis infection. Clin Dev Immunol. 2011;2011:17.
5. Society AT. Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med. 2000;161:1376–95.
6. Comstock GW. How much isoniazid is needed for prevention of tuberculosis among immunocompromised adults? Int J Tuberc Lung Dis. 1999;3(10):847–50.
7. Kim JS, Cho JH, Park GY, Kang YJ, Kwon O, Choi JY, Park SH, Kim YL, Kim HK, Huh S, Kim CD. Comparison of QuantIFERON-TB gold with tuberculin skin test for detection of latent tuberculosis infection before kidney transplantation. Transpl Proc. 2013;45:2899–902.
8. Farhat MGC, Pai M, Menzies D. False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria? Int J Tuberc Lung Dis. 2006;10:1192–204.
9. Herrera VPS, Parsonnet J, Banaei N. Clinical application and limitations of interferon-gamma release assays for the diagnosis of latent tuberculosis infection. Clin Infect Dis. 1031;2011:52.
10. Arend SM, Thijsen SF, Leyten EM, Bouwman JJ, Franken WP, Koster BF, Cobelens FG, van Houte AJ, Bossink AW. Comparison of two interferon-γ assays and tuberculin skin test for tracing tuberculosis contacts. Am J Respir Crit Care Med. 2007;175(6):618–27.
11. Mazurek GH, Jere J, Vernon A, LoBue P, Goldberg S, Castro K, Committee IE. Centers for disease C, prevention: updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection—United States, 2010. MMWR Recomm Rep. 2010;59:1–25.
12. Killikenti J. Poverty, TB, and HIV infection: a vicious cycle. J Health Popul Nutr. 2002;20:281–4.
13. Araujo LS, Mello FCQ, da Silva NBM, Leung JAM, Machado SMA, Sardella IG, Maciel RM, Saad MH. Evaluation of gamma interferon immune response elicited by the newly constructed PstS1-285–374:CFP10 fusion protein to detect Mycobacterium tuberculosis infection. Clin Vaccine Immunol. 2014;21:552–60.
14. Saúde BMDSFm. Manual de recomendações para o controle da Tubercu-lose no Brasil. 2011.
15. Peeling RW, Smith PG, Bossuyt PM. A guide for diagnostic evaluations. Nat Rev Microbiol. 2010;8:52–6.
16. Tavares RC, Salgado J, Moreira VB, Ferreira MA, Mello FC, Leung JW, Fonseca Lde S, Spallek R, Singh M, MH. S: Interferon gamma response to combinations 38 kDa/CFP-10, 38 kDa/MPT-64, ESAT-6/MPT-64 and ESAT-6/CFP-10, each related to a single recombinant protein of
Mycobacterium tuberculosis in individuals from tuberculosis endemic areas. Microbiol Immunol. 2007;51:289–96.
17. Vordermeier HM, Harris DP, Friscia G, Román E, Surcel HM, Moreno C, Pasvol G, Ivanji J. T cell repertoire in tuberculosis: selective anergy to an immunodominant epitope of the 38-kDa antigen in patients with active disease. Eur J Immunol. 1992;22(10):2631–7.
18. Young D, Rees A, Lamb J, Ivanji J. Immunological activity of a 38-kilodalton protein purified from Mycobacterium tuberculosis. Infect Immun. 1986;54:177–83.
19. Hwang WH, Lee WK, Ryoo SW, Yoo KY, Tae GS. Expression, purification and improved antigenicity of the Mycobacterium tuberculosis PstA1 antigen for serodiagnosis. Protein Expr Purif. 2014;95:77–83.
20. Khurshid S, Khalid R, Afzal M, Waheed Akhtar M. Truncation of PstA1 antigen of Mycobacterium tuberculosis improves diagnostic efficiency. Tuberculosis (Edinb). 2013;93:654–9.
21. Palma C, Schiavoni G, Abalsamo L, Mattei F, Piccaro G, Sanchez M, Fernandez C, Singh M, Gabriele L. Mycobacterium tuberculosis PstA1 amplifies IFN-gamma and induces IL-17/IL-22 responses by unrelated memory CD4+ T cells via dendritic cell activation. Eur J Immunol. 2013;43:2386–97.
22. He XYLY, Zhang XG, Liu YD, Wang ZY, Luo FZ, Zhang JP, Wang Q, Yan SM, Wang Yi, Ma LF, Guo J, Dong Yi, Huang XY, Zhuang YH. Clinical evaluation of the recombinant 38 kDa protein of Mycobacterium tuberculosis. Scand J Infect Dis. 2008;40:121–6.
23. de Visser V, Sotgiu G, Lange C, Aabye MG, Bakker M, Bartalesi F, Brat K, Chee CB, Dheda K, Dominguez J, et al. False-negative interferon-gamma release assay results in active tuberculosis: a TBNET study. Eur Respir J. 2013;45:279–85.
24. Zuhiga J, Torres-Garcia T, Santos-Mendoza T, Rodriguez-Reyna TS, Grandaos G, Yunis E. Cellular and humoral mechanisms involved in the control of tuberculosis. Clin Dev Immunol. 2012;2012:193923.
25. Ashenafi S, Aderaye G, Bekele A, Zewdie M, Aseffa G, Hoang AT, Carow B, Habtamu M, Wijkander M, Rottenberg M, Aseffa A. Progression of classical TB is associated with a Th2 immune response signature in combination with elevated levels of SOCS3. Clin Immunol. 2014;151(2):84–99.
26. Dwivedi VP, Bhattacharya D, Chatterjee S, Prasad DV, Chattopadhyay D, Vankar L, Bishai WR, Das G. Mycobacterium tuberculosis directs T helper 2 cell differentiation by inducing interleukin-1β production in dendritic cells. J Biol Chem. 2012;287(40):33656–63.
27. Abebe F, Bjune G. The protective role of antibody responses during Mycobacterium tuberculosis infection. Clin Exp Immunol. 2009;157:235–43.
28. Butera OCT, Carrara S, Casetti R, Vanini V, Meraviglia S, Guggino G, Dieli M, Vecchi M, Laura FN, Marruchella A, Lauretti P, Singh M, Caccamo N, Girardi E, Goletti D. New tools for detecting latent tuberculosis infection: evaluation of RD1-specific long-term response. BMC Infect Dis. 2009;9:182.
29. Goletti D, Butera O, Vanini V, Laura FN, Lange C, Franken KL, Angeletti C, Ottenhoff TH, Girardi E. Response to Rv2628 latency antigen associates with cured tuberculosis and remote infection. Eur Respir J. 2010;36(1):135–43.
30. Leyten EMAS, Prins C, Cobelens FG, Ottenhoff TH, van Dissel JT. Discrepancy between Mycobacterium tuberculosis-specific gamma interferon release assays using short and prolonged in vitro incubation. Clin Vaccine Immunol. 2007;14:880–5.
31. Goletti DVD, Carrara S, Butera O, Bizzoni F, Bernardini G, Amicosante M, Girardi E. Selected RD1 peptides for active tuberculosis diagnosis: comparison of a gamma interferon whole-blood enzyme-linked immunoassay and an enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol. 2006;12:1311–6.
32. Schepers K, Mouchet F, Dirix V, De Schutter J, Jozot K, Verscheure V, Geurts P, Singh M, Van Vooren JP, Mascart F. Long-incubation-time gamma interferon release assays in patients with purified protein derivative, ESAT-6, and/or CFP-10 for the diagnosis of Mycobacterium tuberculosis infection in children. Clin Vaccine Immunol. 2014;21:111–8.
33. Dirix V, Schepers K, Massinga-Laembe M, Wooridia W, Colebunders R, Singh M, Locht C, Kestens L, Mascart F. Group T-ii: added value of long-term cytokine release assays to detect Mycobacterium tuberculosis infection in HIV-infected subjects in Uganda. J Acquir Immune Defic Syndr. 2016;72:344–52.
34. O’Shea MK, Fletcher TE, Beeching NJ, Dedicoat M, Spence D, McShane H, Cunningham AF, Wilson D. Tuberculin skin testing and treatment modulates interferon-gamma release assay results for latent tuberculosis in migrants. PLoS ONE. 2014;9:e97366.
35. Takenami I, Finkimore M, Machado A Jr, Emodi K, Riley LW, Arruda S. Levels of interferon-gamma increase after treatment for latent tuberculosis infection in a high-transmission setting. Pulm Med. 2012; doi:10.1155/2012/757152.
36. Hill PCBR, Fox A, Jackson-Sillah A, Kamasani D, Jeffries DJ, Lugos MD, Donkor SA, Adetifa IM, de Jong BC, Aiken AM, Adegbola RA, McAdam KP. Longitudinal assessment of an ELISPOT test for Mycobacterium tuberculosis infection. PLoS ONE. 2007;4:e192.
37. Pai M, O’Brien R. Serial testing for tuberculosis: can we make sense of T cell assay conversions and reversions? PLoS Med. 2007;4:e208.
38. Higuchi K, Okada K, Harada N, Mori T. Effects of prophylaxis on Quantiferon TB-2G responses among children. Kekkaku. 2008;83:603–9.
39. Higuchi K, Harada N, Mori T. Interferon-gamma responses after isoniazid chemotherapy for latent tuberculosis. Respirolology. 2008;13:468–72.
40. Fujiwara A, Fuji T, Mimura S, Takahashi R, Sakai M, Suzuki S, Kyoto Y, Uwabe Y, Maeda S, Mori T. Tuberculosis contact investigation using interferon-gamma release assay with chest x-ray and computed tomography. PLoS ONE. 2014;9:e85612.
41. Carrara S, Vincenti D, Petrosillo N, Amicosante M, Girardi E, Goletti D. Use of a T cell–based assay for monitoring efficacy of antituberculosis therapy. Clin Infect Dis. 2004;38:754–6.
42. Pathan AA, Wilkinson KA, Klienerman P, McShane H, Davidson RN, Pasvol G, Hill AV, Lahav A. Direct ex vivo analysis of antigen-specific IFN-γ-secreting CD4+ T cells in Mycobacterium tuberculosis-infected individuals: associations with clinical disease state and effect of treatment. J Immunol. 2001;167(9):5217–25.
43. Mancuso JD, Tribble D, Mazurek GH, Li Y, Olsen C, Aronson NE, Geiter L, Goodwin D, Keep LW. Impact of targeted testing for latent tuberculosis infection on mortality and TB incidence. Clin Infect Dis. 2011;53:234–44.

Submit your next manuscript to BioMed Central and we will help you at every step:
- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at www.biomedcentral.com/submit